The most common treatment option for AML is chemotherapy to kill the cancerous cells. Guadecitabine is a new treatment being developed for patients who have not received prior treatment (treatment naive) and are ineligible to undergo intensive chemotherapy. If licenced, guadecitabine would offer a new treatment option for patients that cannot tolerate the standard of care chemotherapy treatments.
Guadecitabine for Treatment of Naive Acute Myeloid Leukaemia
Interventions:
Guadecitabine (SGI-110)
Indications:
Acute myeloid leukaemia (AML)
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2017